This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ADSTILADRIN
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SUO 2024
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Recent Abstracts
Urologic Oncology
Bladder Cancer
Conferences
EAU 2014
EAU 2014 - mCRPC Treatment
Recent Abstracts
#AUA14 - Early experience of radium-223 treatment for metastatic castrate resistant prostate cancer: A preliminary report - Session Highlights
May 20, 2014
EAU 2014 - Poster: A phase 2 trial of prostate specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC)
April 23, 2014
EAU 2014 - Poster: Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate therapy in patients with metastatic castration-resistant prostate cancer? An analysis of abiraterone acetate phase 3 trials
April 15, 2014
EAU 2014 - Poster: Impact of prior endocrine therapy on radiographic progression-free survival in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302
April 15, 2014
EAU 2014 - Does Gleason score at initial diagnosis predict efficacy of abiraterone acetate (AA) therapy in patients with metastatic castration-resistant prostate cancer (mCRPC)? An analysis of AA phase 3 trials - Session Highlights
April 15, 2014
EAU 2014 - Low dose GTx-758 decreases free testosterone to levels similar to orchiectomy in men with metastatic castration resistant prostate cancer (mCRPC) - Session Highlights
April 15, 2014
EAU 2014 - Impact of prior endocrine therapy on radiographic progression-free survival (rPFS) in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Results from COU-AA-302 - Session Highlights
April 15, 2014
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free